

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License number 12-00471-02

Docket or Reference number  
030-01374

Amendment No. 20

St. Mary's Hospital  
Radiology Department  
1800 E. Lake Shore Drive  
Decatur, IL 62525

In accordance with letter dated May 20, 1985, License Number 12-00471-02 is amended as follows:

Item 1 (Name) is changed from St. Mary's Hospital to St. Mary's Hospital, Radiology Department.

Conditions 12. and 19. are amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

F. A. Winters, M.D.

Groups I, II, III, IV and V  
Xenon-133  
In vitro studies

R. J. Roma, M.D.

Groups I, II, III and V  
Iodine-131 for treatment of  
hyperthyroidism and cardiac  
dysfunction  
Xenon-133  
In vitro studies

T. A. Ferry, M.D.

Groups I, II and III  
Iodine-131 for treatment of  
hyperthyroidism and cardiac  
dysfunction  
Xenon-133

J. D. Ambrosini, M.D.

Groups I, II and III  
Iodine-131 for treatment of  
hyperthyroidism and cardiac  
dysfunction  
Soluble phosphorus-32 for treatment  
of polycythemia vera, leukemia  
and bone metastases  
Xenon-133  
In vitro studies

A. J. Kiessel, M.D.

Groups I, II and III  
Xenon-133  
In vitro studies

H. L. Penning, M.D.

Groups I, II and III  
Xenon-133  
In vitro studies

8508120594 850717  
REG3 LIC30  
12-00471-02 PDR

COPY 2

m30

**MATERIALS LICENSE**  
SUPPLEMENTARY SHEET

License number

12-00471-02

Docket or Reference number

030-01374

Amendment No. 20

Carlos Capati, M.D.

Groups I, II and III


Iodine-131 for treatment of  
hyperthyroidism and cardiac  
dysfunction

Soluble phosphorus-32 for treatment  
of polycythemia vera, leukemia  
and bone metastases

Xenon-133

In vitro studies

19. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application received August 1, 1983 including attached ALARA Program; and letters dated December 13, 1983, May 16, 1984 and May 20, 1985. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.



For the U.S. Nuclear Regulatory Commission

Date July 17, 1985

Original Signed  
By B.J. Holt  
Materials Licensing Section, Region III

COPY